ArticleBMC nephrology2025
Treatment options for patients with high anti-PLA2R antibodies in primary membranous nephropathy: a single-center cohort retrospective study.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The value of proteinuria for the administration of rituximab in patients with PLA2R-associated membranous nephropathy: a single-centre retrospective analysis.Annals of medicine · 2026Article
- Comparison of efficacy and safety among four therapeutic regimens in primary membranous nephropathy with high anti-PLA2R antibody titers: a single-center retrospective cohort study.BMC nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe efficacy of rituximab (RTX) in primary membranous nephropathy (PMN) patients with high titers of anti-PLA2R antibodies (aPLA2R) is controversial. This study aimed to evaluate RTX efficacy in PMN patients with high versus low aPLA2R antibodies, and to compare RTX with traditional immunosuppressive regiments in patients with high aPLA2R antibodies.
methodsWe enrolled 118 PMN patients with positive serum aPLA2R antibodies. According to baseline aPLA2R antibody levels, patients treated with RTX were classified into low-titer (L-aPLA2R-RTX) and high-titer (H-aPLA2R-RTX) groups. Meanwhile, high aPLA2R antibody patients were divided into RTX (H-aPLA2R-RTX), tacrolimus (H-aPLA2R-TAC) and cyclophosphamide (H-aPLA2R-CTX) groups according to initial therapy. All patients were followed for 12 months. The primary outcome was complete or partial remission (CR or PR) at 12 months. Secondary outcomes included changes in laboratory parameters, relapse, and adverse events.
resultsAt 12months, 36 patients (74%) in the L-aPLA2R-RTX group and 13 patients (46%) in the H-aPLA2R-RTX group achieved CR or PR (OR = 3.20, 95% CI:1.20-8.49). CR rates were 33% and 11% in the L-aPLA2R-RTX and H-aPLA2R-RTX groups (OR = 4.04, 95% CI:1.06-15.40). Regarding adverse events, there were 22% in the L-aPLA2R-RTX group and 46% in the H-aPLA2R-RTX group (p = 0.03). Relapse rates did not differ significantly between the two groups. At 12 months, CR rates were 11%, 25% and 62% in the H-aPLA2R-RTX, H-aPLA2R-CTX and H-aPLA2R-TAC groups, respectively (p = 0.001). No significant differences were observed among the three groups in terms of CR or PR rates at 12 months, relapse and adverse events.
conclusionPMN patients with high baseline aPLA2R antibody titers had lower remission rates with RTX compared to those with low titers. Among high-titer patients, TAC or CTX were associated with higher remission rates than RTX, particularly TAC. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.